Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
Japan to Give Omicron Boosters to Elderly from Mid-September
Elderly people will be the first in line to receive Omicron-adapted COVID-19 vaccines in Japan for their fourth inoculations, a Japanese health ministry agreed on September 2. The vaccines will be available from mid-September or soon after, with inoculations to get…
To read the full story
Related Article
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
- PM Kishida Vows Earlier Rollout of Omicron Boosters
September 1, 2022
- Japan Mulls Moving Up Omicron Boosters to September
August 31, 2022
- Moderna Files Omicron Bivalent Vaccine in Japan
August 10, 2022
- Japan to Begin BA.1-Based Omicron Booster Program as Early as October
August 9, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
- MHLW Eyes Omicron-Specific Jabs for All Residents Given Primary Inoculations
July 26, 2022
- Omicron-Specific Boosters to Be Introduced This Fall or Later: Panel
July 25, 2022
REGULATORY
- Generic Dispensing Rates Spike on New LLP Coverage Rule: Survey
April 11, 2025
- 250 LDP Lawmakers Sign Petition for Revisiting Budget Cap, Off-Year Cuts
April 11, 2025
- MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
- Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
- Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…